Toxic Epidermal Necrolysis
What's New
Last Posted: May 16, 2024
- Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy.
Yaron Gu et al. JAMA Dermatol 2024 - Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated?
Vy L Bui et al. Pharmacogenet Genomics 2023 - Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in Vietnam.
Khanh Nc Duong et al. Pharmacogenomics 2023 - Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.
Andrew Gibson et al. The Journal of allergy and clinical immunology 2023 151(2) 289-300.e4 - An alternative model for assessing mortality risk in Stevens Johnson syndrome/toxic epidermal necrolysis using a random forests classifier: A pilot study.
Shareef Omar et al. Frontiers in medicine 2022 9935408 - A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine.
Kloypan Chiraphat et al. Pharmaceuticals (Basel, Switzerland) 2021 14(11) - Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art.
Jantararoungtong Thawinee et al. Expert opinion on drug metabolism & toxicology 2021 - Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Tsukagoshi Eri et al. Frontiers in medicine 2021 8644154 - Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.
Yuliwulandari Rika et al. The pharmacogenomics journal 2021 - Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention.
Shanbhag Swapna S et al. Frontiers in genetics 2020 11607532 - Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome.
DeLozier Sarah et al. Journal of the American Medical Informatics Association : JAMIA 2020 Oct - Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.
Chang Chih-Jung et al. Frontiers in pharmacology 2020 11969 - Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice.
Asgarpour Jessica M S et al. Journal of cutaneous medicine and surgery 2020 25(1) 25-29 - Genetic Variants Associated with T-Cell Mediated Cutaneous Adverse Drug Reactions: A Prisma-Compliant Systematic Review - an EAACI Position Paper.
Oussalah Abderrahim et al. Allergy 2020 Jan - Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients
F Capule et al, PGX journal. January 3, 2020 - Genetic Predisposition to Anticonvulsant Hypersensitivity
M Pirmohamed, CPT, September 2019 - Genetic testing for prevention of severe drug-induced skin rash.
Alfirevic Ana et al. The Cochrane database of systematic reviews 2019 Jul 7CD010891 - Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
Choi Hyunmi et al. Epilepsia 2019 Jun - Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan R-Y et al. Clinical pharmacology and therapeutics 2017 102(1) 86-97 - Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations.
Firer Maria et al. Epilepsia 2018 59(7) 1469-1470
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 14, 2024
- Content source: